1. Pink Sheet
  2. >>Archive

Medivation Aims To Capture Prostate Cancer Market, One Trial At A Time

 
• By Michael Goodman

Phase III data for Medivation's MDV3100 suggest the prostate cancer drug stands to unseat J&J’s market leader Zytiga in many of the disease settings.

Early results indicate that Medivation Inc. MDV3100 may reach the market with, among other advantages, a strong survival benefit that will position the androgen receptor signaling blocker to make considerable waves in the volatile and lucrative castrate-resistant prostate cancer market.

On Nov. 3, San Francisco-based Medivation released interim data from a pivotal trial of MDV3100 in men with metastatic castration-resistant prostate cancer who had failed prior chemotherapy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.